FindMyKOL

Randa Loutfi, MD

Basic profile

Henry Ford Health

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionDetroit, MI · MidwestSpecialtyMedical OncologyFocusOncology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Randa Loutfi is an Oncology physician affiliated with Henry Ford Health. OpenAlex indexes 16 publications with 2,175 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
16publications

Publications indexed by OpenAlex. Counts exclude supporting files.

2,175citations

Citations across these publications.

8h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
7companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • AstraZeneca Pharmaceuticals LP
    Program year20254 payments
    $236
  • Gilead Sciences, Inc.
    Program year20253 payments
    $190
  • Merck & Co.
    Program year20251 paymentResearch
    $175
All 18 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    59.7%
    Aromatase Inhibitor45.3%
    Anastrozole64%Letrozole27%Exemestane9%
    Part D≥100 patients
    Kinase inhibitor12.1%
    Verzenio39%Kisqali32%Ibrance20%Alunbrig9%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    13.6%
    Serotonin-3 Receptor Antagonist5.2%
    Ondansetron Odt75%Ondansetron Hcl25%
    Part D<11 patients
    Potassium supplement3.8%
    Potassium Chloride64%Klor-Con M2036%
    Part D<11 patients

    + 3 more classes in this area

  • Nervous system

    7%
    Phenothiazine2.3%
    Prochlorperazine Maleate100%
    Part D≥22 patients
    Gabapentinoids1.9%
    Gabapentin100%
    Part D<11 patients

    + 2 more classes in this area

Where care is delivered (Part B)91.1% facility · 8.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”